440
Participants
Start Date
April 1, 2021
Primary Completion Date
November 17, 2021
Study Completion Date
March 17, 2022
PrEP-RN
Patients randomized to the intervention arm will be counseled on HIV risk factors in general, their HIV risk factors in particular, and prevention methods, inclusive of PrEP (Emtricitabine 200 mg/Tenofovir disoproxil fumarate 300 mg).
Johns Hopkins Outpatient Center, Baltimore
Collaborators (1)
Gilead Sciences
INDUSTRY
Johns Hopkins University
OTHER